clindamycin + piperacillin + tazobactam

Clindamycin + piperacillin + tazobactam is a combination of three antibiotics used together, typically as empiric therapy for severe polymicrobial infections such as necrotizing soft tissue infections (NSTIs) and other life-threatening or hospital-acquired infections.

• Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, providing activity against many anaerobic bacteria and some gram-positive organisms. It also suppresses toxin production in certain bacteria such as group A Streptococcus.
• Piperacillin is an extended-spectrum ureidopenicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins; it has broad-spectrum activity against gram-negative, some gram-positive, and anaerobic bacteria.
• Tazobactam is a beta-lactamase inhibitor that protects piperacillin from degradation by beta-lactamase enzymes produced by resistant bacteria, thereby extending its spectrum of activity.

This triple combination provides very broad coverage against aerobic and anaerobic pathogens including resistant strains often encountered in severe mixed infections. It is most commonly used in critical care settings where rapid empiric coverage for multiple potential pathogens—including toxin-producing organisms—is required.